Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
About Us
News and Events
My HPRA:
Login
Register
About Us
Our Mission, Vision and Values
What We Regulate and How We Regulate
Our Strategic Plan 2021 – 2025
Contact Us
Our Structure
Patient Forum
Publications & Forms
Standards of Service
Privacy and Data Protection
Information and transparency
Consultations
Quality Management
Recruitment
Report an Issue
Legislation
Extranets
News and Events
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMA recommends first COVID-19 vaccine for authorisation in the EU
News Category:
Regulatory news
Date:
21/12/2020
The European Medicines Agency (EMA) has
recommended
granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. The EMA’s scientific opinion paves the way for the first marketing authorisation of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.
The EMA’s human medicines committee (CHMP) has completed its rigorous evaluation of Comirnaty, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available to recommend a formal conditional marketing authorisation. This will provide a controlled and robust framework to underpin EU-wide vaccination campaigns and protect EU citizens.
View EMA Press Release
The CHMP incorporates scientific expertise from all the national competent authorities in Europe, including the HPRA.
Further information
The
product information
approved by the CHMP for Comirnaty contains prescribing information for healthcare professionals, a package leaflet for members of the public and details of conditions of the vaccine’s authorisation.
More information is available in an
overview of the vaccine in lay language
, including a description of the vaccine’s benefits and risks and why the EMA recommended its authorisation in the EU.
« Back
Date Printed: 04/05/2024